Skip to Content

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCTHN1244


Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

Principal Investigator(s)

Leora Horn


  • Protocol No. VICCTHN1244
  • Open Date: 07/25/2012
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the safety/tolerability of X-396 and determine the maximum tolerated dose (MTD) of X-396 as a single agent.
  • Disease Sites: Phase I; Lung; Non Small Cell
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: X-396
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01625234
  • Secondary Protocol No: X396-CLI-101


This research study is being done to evaluate the safety of an investigational drug, X-396, and to determine the best dose to use for future studies.


Not provided. Please call for more information.